Pfizer is developing a bivalent vaccine for children ages 5 to 11, while Moderna’s would be eligible for those ages 6 to 17.
“If authorized by FDA, CDC anticipates a recommendation for bivalent COVID-19 vaccine as a booster for pediatric age groups in early to mid-October,” the agency said. “It is expected that if bivalent boosters are authorized for individuals aged 5 years and older as a booster, monovalent mRNA COVID-19 vaccines may no longer be authorized as booster doses.”
At present, Pfizer’s updated booster is authorized for people 12 and up, and Moderna’s is authorized for adults 19 and older. The CDC formally recommended the boosters for these age groups Sept. 1, one day after the FDA granted emergency use authorization.
Learn more here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
